knowledge -WSS

knowledge

author：focus 2025-09-27 23:02:29 - browse：9538

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

WSS

Fauci's latest grilling in Congress: 9 hours, behind closed doors

American taxpayers paid $1.8 trillion in health care costs in 2022

STAT Virtual Event: JPM Recap, Live!

Boston's new lab space is opening empty

Readout Newsletter: CAR

Profiling embryos to choose those with higher IQs is almost a reality

explore

knowledge

entertainment

Walensky prepares to leave CDC — and Congress — behind

As AI in medicine takes off, can 'human in the loop' prevent harm?

23andMe had bad news about my health. I wish a person had delivered it

A preacher's new calling: Diversifying neuroscience research

How one medical school became remarkably diverse

Study suggests new cause of Down syndrome: cells linked to aging

Moonlake's readout produced a cash windfall. Risks remain

Life science postdocs should get big pay hike, NIH panel says

The high cost of giving birth even with insurance

Allen Institute goes after foundational questions, CEO Costa says

entertainment

EPA limits use of carcinogenic gas for sterilizing medical devices

First U.S. drug developed to treat liver disease MASH is approved

Merck to acquire Harpoon Therapeutics for $680 million

FDA early review: GLP

As AI in medicine takes off, can 'human in the loop' prevent harm?

Readout Newsletter: CAR

focus

leisure time

entertainment

explore